Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701140 | 0.84 | POLB (0.42) | ALDH1A1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6700329 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1MAPK1HTT | |
| SCHEMBL6696562 | 0.74 | PTGER4 (0.42) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6700334 | 0.74 | ABCB1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL6700986 | 0.72 | MAPK1 (0.36) | ALDH1A1TSHRL3MBTL1MAPK1CACNA1H | |
| SCHEMBL6703428 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TSHRL3MBTL1MAPK1P2RY14 | |
| SCHEMBL6705194 | 0.71 | SMN1; SMN2 (0.47) | ALDH1A1 | |
| SCHEMBL6699931 | 0.70 | CLPP (0.38) | MAPK1SIGMAR1 | |
| SCHEMBL6704242 | 0.69 | PTGER4 (0.36) | ALDH1A1TSHRL3MBTL1CACNA1GCACNA1H | |
| SCHEMBL6694967 | 0.68 | MMP13 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | ALDH1A1 221/4885TSHR 4387/4885L3MBTL1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.